Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EU103 in Advanced or Metastatic Solid Tumors
NCT05798026Phase 1Recruiting
- Sponsor
- Eutilex Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of EU103 in solid tumor (6 cohorts), sponsored by Eutilex Co., Ltd. Primary endpoints: Adverse Events and Serious Adverse Events at 30 months, Dose Limiting Toxicity and 3 more. Started Aug 2023; status: recruiting.
02
Drugs
EU103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05798026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798026.